Related Experiment Video

Updated: Aug 15, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

[Plasma renin activity in patients with coronary arteriosclerosis with different types of hyperlipoproteinemia]

V V Gorbachev, G A Vecherskiĭ

    Kardiologiia
    |February 1, 1976
    PubMed

    Insights

    Patients with coronary atherosclerosis exhibit elevated plasma renin activity, particularly those with hyperlipoproteinemia and arrhythmias. This finding suggests a link between renin levels and coronary artery disease severity.

    Area of Science:

    • Cardiology
    • Endocrinology
    • Biochemistry

    Context:

    • Coronary atherosclerosis is a significant health concern.
    • Lipid metabolism disorders, such as hypercholesterolemia and hypertriglyceridemia, are common in patients with coronary atherosclerosis.
    • Plasma renin activity is a key component of the renin-angiotensin-aldosterone system.

    Purpose:

    • To investigate the relationship between plasma renin activity and different clinical forms of coronary atherosclerosis.
    • To explore the correlation between plasma renin activity and various types of hyperlipoproteinemia in patients with coronary atherosclerosis.

    Summary:

    • The study examined 142 patients with coronary atherosclerosis and 40 controls.
    • Elevated plasma renin activity was observed in patients with coronary atherosclerosis, especially in the pain form and arrhythmic forms.
    • Higher renin activity was associated with Type II and Type III hyperlipoproteinemia, paroxysmal arrhythmia, and cardiac fibrillation.

    Impact:

    • This research highlights the potential role of plasma renin activity as a biomarker in coronary atherosclerosis.
    • Understanding the link between renin activity and hyperlipoproteinemia may lead to novel therapeutic strategies.
    • Findings contribute to the understanding of the pathophysiology of coronary artery disease.

    More Related Videos

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

    A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

    Published on: October 26, 2020

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation06:47

    Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

    Published on: January 28, 2021

    Related Concept Videos

    Antihypertensive Drugs: Direct Renin Inhibitors01:25

    Antihypertensive Drugs: Direct Renin Inhibitors

    The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

    Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

    Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
    These markers indicate stress or strain on the heart muscle:
    Natriuretic Peptides (BNP)
    Cardiac myocytes produce these hormones in response to ventricular stretching...
    Coronary Artery Disease IV: Preventive Measures01:26

    Coronary Artery Disease IV: Preventive Measures

    Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    Atherosclerosis III: Management01:26

    Atherosclerosis III: Management

    Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...